133 related articles for article (PubMed ID: 38892196)
1. Nonclinical Evaluation of Single-Mutant
Ruiz-Lara G; Costa-Silva TA; Muso-Cachumba JJ; Cevallos Espinel J; Fontes MG; Garcia-Maya M; Rahman KM; Rangel-Yagui CO; Monteiro G
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892196
[TBL] [Abstract][Full Text] [Related]
2. A protease-resistant Escherichia coli asparaginase with outstanding stability and enhanced anti-leukaemic activity in vitro.
Maggi M; Mittelman SD; Parmentier JH; Colombo G; Meli M; Whitmire JM; Merrell DS; Whitelegge J; Scotti C
Sci Rep; 2017 Nov; 7(1):14479. PubMed ID: 29101342
[TBL] [Abstract][Full Text] [Related]
3. Novel mutant of Escherichia coli asparaginase II to reduction of the glutaminase activity in treatment of acute lymphocytic leukemia by molecular dynamics simulations and QM-MM studies.
Ardalan N; Mirzaie S; Sepahi AA; Khavari-Nejad RA
Med Hypotheses; 2018 Mar; 112():7-17. PubMed ID: 29447943
[TBL] [Abstract][Full Text] [Related]
4. Comparative immunogenicity and structural analysis of epitopes of different bacterial L-asparaginases.
Pokrovsky VS; Kazanov MD; Dyakov IN; Pokrovskaya MV; Aleksandrova SS
BMC Cancer; 2016 Feb; 16():89. PubMed ID: 26867931
[TBL] [Abstract][Full Text] [Related]
5. Functional and structural evaluation of the antileukaemic enzyme L-asparaginase II expressed at low temperature by different Escherichia coli strains.
de Moura WAF; Schultz L; Breyer CA; de Oliveira ALP; Tairum CA; Fernandes GC; Toyama MH; Pessoa-Jr A; Monteiro G; de Oliveira MA
Biotechnol Lett; 2020 Nov; 42(11):2333-2344. PubMed ID: 32638188
[TBL] [Abstract][Full Text] [Related]
6. Hyperthermophilic asparaginase mutants with enhanced substrate affinity and antineoplastic activity: structural insights on their mechanism of action.
Bansal S; Srivastava A; Mukherjee G; Pandey R; Verma AK; Mishra P; Kundu B
FASEB J; 2012 Mar; 26(3):1161-71. PubMed ID: 22166247
[TBL] [Abstract][Full Text] [Related]
7. Mutations in subunit interface and B-cell epitopes improve antileukemic activities of Escherichia coli asparaginase-II: evaluation of immunogenicity in mice.
Mehta RK; Verma S; Pati R; Sengupta M; Khatua B; Jena RK; Sethy S; Kar SK; Mandal C; Roehm KH; Sonawane A
J Biol Chem; 2014 Feb; 289(6):3555-70. PubMed ID: 24297177
[TBL] [Abstract][Full Text] [Related]
8. L-Asparaginase Isolated from Phaseolus vulgaris Seeds Exhibited Potent Anti-Acute Lymphoblastic Leukemia Effects In-Vitro and Low Immunogenic Properties In-Vivo.
Mohamed SA; Elshal MF; Kumosani TA; Aldahlawi AM; Basbrain TA; Alshehri FA; Choudhry H
Int J Environ Res Public Health; 2016 Oct; 13(10):. PubMed ID: 27754445
[No Abstract] [Full Text] [Related]
9. Bacterial l-asparaginases for cancer therapy: Current knowledge and future perspectives.
Ghasemian A; Al-Marzoqi AH; Al-Abodi HR; Alghanimi YK; Kadhum SA; Shokouhi Mostafavi SK; Fattahi A
J Cell Physiol; 2019 Nov; 234(11):19271-19279. PubMed ID: 30993718
[TBL] [Abstract][Full Text] [Related]
10. A Novel l-Asparaginase with low l-Glutaminase Coactivity Is Highly Efficacious against Both T- and B-cell Acute Lymphoblastic Leukemias
Nguyen HA; Su Y; Zhang JY; Antanasijevic A; Caffrey M; Schalk AM; Liu L; Rondelli D; Oh A; Mahmud DL; Bosland MC; Kajdacsy-Balla A; Peirs S; Lammens T; Mondelaers V; De Moerloose B; Goossens S; Schlicht MJ; Kabirov KK; Lyubimov AV; Merrill BJ; Saunthararajah Y; Van Vlierberghe P; Lavie A
Cancer Res; 2018 Mar; 78(6):1549-1560. PubMed ID: 29343523
[TBL] [Abstract][Full Text] [Related]
11. Improved pharmacokinetic and pharmacodynamic profile of a novel PEGylated native Erwinia chrysanthemi L-Asparaginase.
Modi T; Gervais D
Invest New Drugs; 2022 Feb; 40(1):21-29. PubMed ID: 34468906
[TBL] [Abstract][Full Text] [Related]
12. The E. coli L-asparaginase V27T mutant: structural and functional characterization and comparison with theoretical predictions.
Strzelczyk P; Zhang D; Wlodawer A; Lubkowski J
FEBS Lett; 2022 Dec; 596(23):3060-3068. PubMed ID: 36310372
[TBL] [Abstract][Full Text] [Related]
13. Cloning and characterization of Halomonas elongata L-asparaginase, a promising chemotherapeutic agent.
Ghasemi A; Asad S; Kabiri M; Dabirmanesh B
Appl Microbiol Biotechnol; 2017 Oct; 101(19):7227-7238. PubMed ID: 28801829
[TBL] [Abstract][Full Text] [Related]
14. L-asparaginase genes in Escherichia coli: isolation of mutants and characterization of the ansA gene and its protein product.
Spring KJ; Jerlström PG; Burns DM; Beacham IR
J Bacteriol; 1986 Apr; 166(1):135-42. PubMed ID: 3514575
[TBL] [Abstract][Full Text] [Related]
15. Discovery of human-like L-asparaginases with potential clinical use by directed evolution.
Rigouin C; Nguyen HA; Schalk AM; Lavie A
Sci Rep; 2017 Aug; 7(1):10224. PubMed ID: 28860480
[TBL] [Abstract][Full Text] [Related]
16. Crystal structure of active site mutant of antileukemic L-asparaginase reveals conserved zinc-binding site.
Borek D; Kozak M; Pei J; Jaskolski M
FEBS J; 2014 Sep; 281(18):4097-111. PubMed ID: 25040257
[TBL] [Abstract][Full Text] [Related]
17. A critical review on properties and applications of microbial l-asparaginases.
Krishnapura PR; Belur PD; Subramanya S
Crit Rev Microbiol; 2016 Sep; 42(5):720-37. PubMed ID: 25865363
[TBL] [Abstract][Full Text] [Related]
18. Structural and functional insights into Erwinia carotovora L-asparaginase.
Papageorgiou AC; Posypanova GA; Andersson CS; Sokolov NN; Krasotkina J
FEBS J; 2008 Sep; 275(17):4306-16. PubMed ID: 18647344
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future.
Avramis VI; Panosyan EH
Clin Pharmacokinet; 2005; 44(4):367-93. PubMed ID: 15828851
[TBL] [Abstract][Full Text] [Related]
20. [Suppression of telomerase activity leukemic cells by mutant forms of Rhodospirillum rubrum L-asparaginase].
Pokrovskaya MV; Zhdanov DD; Eldarov MA; Aleksandrova SS; Veselovskiy AV; Pokrovskiy VS; Grishin DV; Gladilina JA; Sokolov NN
Biomed Khim; 2017 Jan; 63(1):62-74. PubMed ID: 28251953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
